Everist Genomics Gets CLIA OK | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Everist Genomics today said that it has received the US Clinical Laboratory Improvement Amendment certification required for it to launch its OncoDefender-CRC assay.

The Ann Arbor, Mich.-based firm plans to officially launch the test, which is a gene-based assay used in stage I and II colon cancer and stage I rectal cancer patients to assess the risk of recurrence following surgery, later this month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.